Eryhtropoetin induced 18 F-PSMA-11 bone marrow sink effect.

Eur J Nucl Med Mol ImagingJun 10, 2026 (epub)
Case ReportOncology (Medical)Nuclear MedicineOpen access

Justine Maes, Alex Maes, Kristoff Muylle et al.

✦ AI-curated · Sources linked

Case in brief

A patient with metastatic prostate adenocarcinoma underwent 18F-PSMA-11 PET/CT imaging after receiving 177Lu-PSMA-617 treatment. The imaging revealed intense, homogeneous tracer uptake in the bone marrow, while specific bone metastases showed reduced visibility. The patient had received erythropoietin prior to imaging, which likely stimulated neovasculature in the bone marrow, affecting tracer distribution and interpretation.

What made this case unusual

The case highlights a unique imaging phenomenon where erythropoietin administration led to diffuse bone marrow uptake of 18F-PSMA-11, obscuring the visibility of known metastases.

Diagnostic / clinical pearl

Clinicians should consider the effects of erythropoietin on bone marrow imaging when interpreting 18F-PSMA-11 PET/CT scans, as it can lead to misleading results.

Why it matters

Understanding the impact of erythropoietin on imaging can prevent misinterpretation of PET/CT results and avoid unnecessary treatment adjustments or toxicity.

Source

PubMed · PMID 42265325Free full text on PubMed Central

Published in Eur J Nucl Med Mol Imaging. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.